Delisting Determination,The Nasdaq Stock Market, LLC,
January 8, 2019, Biostar Pharmaceuticals, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Biostar Pharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on January 18, 2019. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5250(c)(1).
The Company was notified of the Staffs determination on
July 19, 2018.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
September 17, 2018, denying the Company continued listing
and notified the Company that trading in the Companys
securities would be suspended on September 19, 2018.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on November 1, 2018.